Medindia
Medindia LOGIN REGISTER
Advertisement

QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms

Wednesday, January 24, 2018 General News
Advertisement
Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines

HILDEN, Germany, and GERMANTOWN, Maryland, January 23, 2018 /PRNewswire/ --
Advertisement

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.
Advertisement

Click here for the full press release

https://corporate.qiagen.com/newsroom/press-releases/2017/20180119_ipsogen_jak2?sc_lang=en

Contacts: QIAGEN Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711 Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826

SOURCE Qiagen N.V.

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close